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ABSTRACT 
 
Background: Adrenocortical carcinoma (ACC) is a rare endocrine malignancy 
with a poor prognosis and few therapeutic options. Stathmin1 (STMN1) is a 
cytosolic protein involved in microtubule dynamics, which has been implicated 
in carcinogenesis and more aggressive behavior in multiple epithelial 
malignancies. Here we aimed to evaluate the expression of STMN1 in ACC 
and to elucidate how this may contribute to its malignant phenotype. 
 
Methods: STMN1 was identified as a highly differentially expressed gene in 
human samples of adrenocortical carcinoma submitted for high throughput 
RNA-sequencing compared to benign adrenal tumors. Expression was 
confirmed by qRT-PCR, Western blot, and immunohistochemical (IHC) 
staining of a tissue microarray (TMA) from two independent cohorts. The 
biologic relevance of this target was investigated in the NCI-H295R ACC cell 
line by lentivirus-mediated silencing of STMN1. In vitro phenotypic changes 
were assessed for cell viability, cell-cycle alterations, invasion, migration, and 
anchorage-independent growth.  
 
Results: Differential gene expression demonstrated over an eight-fold 
increase in STMN1 mRNA in malignant compared to benign adrenal tissue 
(p<2.4E-07). IHC showed significantly higher expression of STMN1 protein in 
ACC compared to normal and benign tissues (p<0.05, p<0.01, respectively). 
	  We achieved more than 70% reduction of STMN1 expression in NCI-H295R 
by lentivirus-mediated short hairpin RNA (shRNA) delivery. STMN1 
knockdown resulted in decreased cell viability (p<0.01), cell-cycle arrest at 
G0/G1 (p<0.01), and increased apoptosis (p<0.01) in stressed, serum-starved 
conditions compared to scramble shRNA controls. STMN1 knockdown also 
decreased migration (p<0.05), invasion (p<0.05), and anchorage-independent 
growth (p<0.01) compared to controls.  
 
Conclusion: STMN1 is overexpressed in human ACC samples and 
knockdown of this target in vitro resulted in a less aggressive phenotype of 
ACC, particularly under serum-starved conditions. Further study is needed to 
investigate the feasibility of interfering with STMN1 as a potential therapeutic 
target. 
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INTRODUCTION 
 
Adrenocortical carcinoma (ACC) is a rare but deadly malignancy 
representing 0.7-2.0 cases of carcinoma per million per year and manifesting 
in a 5-year overall survival of 37-47% [1–3]. Although some patients present 
with symptoms from hormonal hypersecretion or mass effect, detection of 
ACC is often incidental and at an advanced stage. En-bloc, R0 surgical 
resection remains the mainstay of therapy as the only potential curative option 
for patients with ACC [4,5].  For those unable to undergo resection or with 
extensive tumor burden, adrenolytic or conventional chemotherapeutic 
regimens yield modest results, and their use is limited by toxicity [1,6–8]. While 
there is much ongoing research to help understand the pathogenesis of this 
disease and improve outcomes, attempts at targeted therapy against vascular 
endothelial growth factor (VEGF) receptor thus far have failed to show survival 
benefit [9]. Similarly disappointing results were shown in a recent phase 3 
randomized, controlled trial of lisitinib, an oral small molecule inhibitor of 
insulin growth factor (IGF)-1 receptor [10–12]. Consequently, it is imperative to 
continue the search for novel and more effective therapeutic targets for ACC. 
 In an effort to further understanding of the pathogenesis of this disease 
and to identify potential targets for treatment in ACC, we performed RNA-
sequencing of a set of 38 human adrenal samples comprised of normal 
adrenal cortex (NML), adrenal adenomas (AA) and adrenocortical carcinomas 
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(ACC).  Given the recent unsuccessful small-molecule inhibitor trials against 
transmembrane receptors, we focused our attention on the differential 
expression of cytosolic proteins in the malignant compared to benign samples. 
Thereby, we identified STMN1 to be among the most highly differentially 
expressed genes.  
 Stathmin 1 (STMN1, also known as p17, p18, p19, LAP 18, metablastin, 
and oncoprotein 18) is a 19kD cytosolic phosphoprotein, involved in the 
regulation of microtubule dynamics by inhibition of tubulin polymerization and 
promotion of microtubule depolymerization [13]. Its role in carcinogenesis has 
been investigated in a variety of tumor types and its expression has been 
associated with tumor progression and poor prognosis in breast, gastric, 
esophageal, endometrial, hepatocellular, oral squamous cell, and colorectal 
cancers [14–20].  Furthermore, STMN1 has been exploited to understand its 
role in oncogenesis and for examining its therapeutic potential. In colorectal 
cancer, silencing STMN1 inhibited colorectal cancer metastases by 
downregulating transcription of metastatic drivers and enhanced tumor 
chemoresponse to 5-fluorouracil [21]. In neuroblastoma, STMN1 suppression 
reduced lung metastases in a mouse model [22]. Wang et al. also showed that 
STMN1 knockdown improved sensitivity to tubulin-targeting drugs paclitaxel 
and vinblastine in esophageal squamous cell carcinoma [23]. Despite this 
growing body of literature on the importance of STMN1 in the pathogenesis of 
a number of epithelial malignancies, its role in adrenocortical carcinoma has 
not yet been elucidated.  
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 Herein, we report on the expression of STMN1 in ACC and 
demonstrate its role in the phenotype of ACC in vitro. This study provides a 
potential stepping-stone from which to pursue targeted therapy against this 
highly heterogeneous and aggressive malignancy. 
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MATERIALS AND METHODS 
 
Tissue Specimens 
After obtaining approval from the Weill Cornell Medical College 
Institutional Review Board, adrenalectomy specimens from patients 
undergoing surgery at Weill Cornell Medical College/New York Presbyterian 
Hospital from June 2000 to September 2011 were identified using a 
prospectively maintained tissue database.  Samples were collected after 
written informed consent was obtained from each patient. Tissues were snap-
frozen in liquid nitrogen at the time of surgery and stored at -80°C.  In addition, 
5 tumor samples were obtained from the Cooperative Human Tissue Network, 
funded by the National Cancer Institute (NCI). Thirteen ACC, 14 AA, and 11 
NML samples were chosen for further analysis.  An endocrine pathologist (TS) 
reviewed each case to ensure correct diagnosis. 
 
RNA Extraction and Next-Generation RNA Sequencing 
RNA was extracted from 38 frozen tissue samples and cells using the 
RNeasy Mini Kit (Qiagen, Venlo, Netherlands) according to the manufacturer’s 
instructions.  RNA quality was assessed with the Agilent 2100 Bioanalyzer 
(Agilent Technologies, Santa Clara, CA) and RNA quantity was assessed with 
the NanoDrop (Thermo Fischer Scientific, Wilmington, DE). An RNA Integrity 
Number (RIN) of ≥8 was required for library preparation. Samples were 
prepared for Next-Generation sequencing with the TruSeq RNA sample prep 
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kit (Illumina, San Diego, CA). Paired-end cluster generation was performed 
utilizing the TruSeq SBS Kit v3-Hs in conjunction with the TruSeq PE Cluster 
Kit v3-cBot-HS on the HiSeq2000 (Illumina, San Diego, CA). Illumina HiSeq 
control software performed a real-time analysis of the sequencing runs. Three 
samples were run in each lane using paired end mode (2 x 51 cycles).  
 A median of 1.2 x108 reads (range 9.2 x107 and 1.63 x108 reads) was 
obtained per sample. The mean perfect index reads percentage was 
87.7±3.5%. These values were within the parameters suggested by Illumina. 
Reads were aligned to the human genome (GRCH37/hg19) using TopHat 
[24,25] (http://tophat.cbcb.umd.edu/) with default parameters and mRNA levels 
quantified using CuffLinks [26] (http://cufflinks.cbcb.umd.edu/) with upper-
quartile and GC normalization.  Differentially expressed genes were identified 
using the LIMMA approach comparing ACC (malignant) v NML+AA (benign), 
and ranked by false discovery rate (FDR) and absolute log fold change >2. An 
FDR of ≤0.05 was considered significant. This yielded several hundred 
differentially expressed genes. To narrow this, we restricted our search to 
cytosolic proteins using the Gene Ontology database GO:005829 annotation.  
 
Immunohistochemistry Staining and Grading 
The Cornell tissue microarray (TMA) was constructed from formalin-
fixed paraffin embedded (FFPE) tissue blocks from the same 38 patients 
submitted for sequencing, with an additional 14 ACC samples only available 
as FFPE blocks. Three cores of 0.6mm were taken from areas of high tumor 
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density as identified by TS on corresponding hematoxylin and eosin (H&E) 
stained slides. Each case was represented by triplicate cores.  
Immunohistochemical staining of STMN1 (Rabbit Polyclonal, Dilution at 
1:50, Cell Signaling) was accomplished using the Bond III Autostainer (Leica 
Microsystems, Buffalo Grove, Illinois). Formalin-fixed, paraffin-embedded 
tissue sections were first baked and deparaffinized. Antigen retrieval was 
followed using the Bond Epitope Retrieval Solution 2(ER2) at 99-100°C for 20 
minutes (Leica Microsystems, Buffalo Grove, Illinois). Sections were then 
subjected to sequential incubations with primary antibody, post-primary, 
polymer, endogenous peroxidase block, diaminobenzidine (DAB) and 
hematoxylin for 15, 8, 8, 5, 10 and 5 minutes (Bond Polymer Refine Detection; 
Leica Microsystems), respectively. Finally, stained sections were dehydrated 
and mounted in CytosealTM XYL (Richard-Allan Scientific, Kalamazoo, MI). 
   
Grading of STMN1 staining was performed by an endocrine pathologist 
(TS) using a semi-quantitative scoring system. A STMN1 score of 0, 1+, 2+, or 
3+ was considered to represent no staining, weak staining, moderate staining, 
or strong staining, respectively. Appropriate positive and negative (incubation 
with secondary antibody only) controls were stained in parallel with each round 
of immunohistochemistry. 
A validation TMA from MD Anderson was used for confirmation of 
expression findings.  This cohort consisted of 39 ACCs, 19 AAs, and 19 NML 
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samples.  STMN1 staining was performed and analyzed independently by 
pathologist SG.  
             
Reverse Transcription and Quantitative PCR 
First-strand cDNA synthesis was performed using M-MLV Reverse 
Transcriptase (Life Technologies, Carlsbad, CA) according to the 
manufacturer’s instructions. The quantitative PCR (qPCR) was performed with 
the TaqMan® Gene Expression Assay (Life Technologies, Carlsbad, CA) 
using predesigned primers for STMN1 (Hs01027515_gH) and GAPDH 
(Hs02758991_g1) according to the manufacturer’s instructions using the 
Lightcycler 480 II (Roche Diagnostics, Indianopolis, IN). All PCR reactions 
were performed in a final volume of 10uL with 1uL of cDNA template. The 
following thermal cycling parameters were used: incubation at 50°C for two 
minutes, denaturing at 95°C for ten minutes, 45 cycles of the amplification 
step (denaturation at 95°C for 15 seconds and annealing/extension at 60°C for 
one minute). STMN1 gene expression was normalized relative to the 
housekeeping gene GAPDH.  All experiments were performed in triplicate and 
gene expression values were calculated according to the ∆∆CT method [27], 
using cDNA derived from NCI-H295R cells as the reference.  
 
Protein Preparation and Western Blot Analysis 
Protein was extracted with RIPA-Lysis buffer (Santa Cruz 
Biotechnology, Santa Cruz, CA).  Protein concentration was determined by the 
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Pierce BCA assay method according to the manufacturer’s protocol (Thermo 
Scientific, Waltham, MA). Western blots were performed with 10 micrograms 
of protein per lane using semi-dry transfer and horseradish-peroxidase (HRP)-
conjugated antigen retrieval system as described previously [28].  STMN1 
antibody was obtained from Cell Signaling (Danvers, MA) and it was 
normalized to GAPDH or Actin (Cell Signaling, Danvers, MA). Quantification of 
relative densities was completed using ImageJ software (NIH).  
 
Cell Culture 
The adrenocortical carcinoma cell line NCI-H295R (ATCC, Rockville, 
MD) is an angiotensin II-responsive steroid-producing line isolated from a 48-
year old female patient with ACC in 1980 [29]. It is the most widely used 
commercially available ACC cell line. The cells were grown and maintained in 
DMEM/F12 supplemented with 1% ITS+ Premix (BD Biosciences, San Jose, 
CA), 2.5% NuSerum I (BD Biosciences), and 1% 
Penicillin/Streptomycin/Amphotericin (P/S/A) in a standard humidified 
incubator at 37°C in a 5% CO2 atmosphere. Cells were routinely subcultured 
and medium was changed every 2-3 days. For particular experiments, serum 
free media was utilized for specific durations consisting of DMEM/F12 
supplemented with 1% P/S/A only. 
 
Lentivirus-mediated Short Hairpin RNA (shRNA) Knockdown of Gene 
Expression 
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To knock down STMN1 expression, OP18 shRNA transduction-ready 
lentiviral particles containing three STMN1-specific constructs added in equal 
ratios were purchased (SantaCruz Biotechnology Inc, Santa Cruz, CA).  The 
hairpin sequences were: 5’-
GATCCCCAGATCCAGACTGTAAGATTCAAGAGATCTTACAGTCTGGATC 
TGG TTTTT-3’, 5’-
GATCCGGGAGAAACTGAAAGTGTTTTCAAGAGAAACACT TTCAG 
TTTCTCCCTTTTT-3’, and 5’-GATCCCCTCCTGGTTGATACTTGTTTCA 
AGAGAACAAGTATCAACCAGGAGGTTTTT-3’. Transduction was carried out 
according to the manufacturer’s instructions. Briefly, 1x105 H295R cells were 
seeded in complete media in one well in a 24-well plate. After 48 hours, media 
was changed to complete media with 5 ug/mL Polybrene (Santacruz 
Biotechnology Inc, Santa Cruz, CA) and 5x105 lentiviral particles were added. 
24 hours post-infection, Polybrene-containing media was removed and 
replaced with regular complete media. Cells were split 1:3 once appropriate 
and stable clones expressing the shRNA were selected by Puromycin 
(Santacruz Biotechnology Inc, Santa Cruz, CA) selection at 5ug/mL, as 
predetermined via a kill curve on uninfected cells. The same protocol was 
simultaneously carried out for control shRNA (Santacruz Biotechnology Inc, 
Santa Cruz, CA) containing a construct encoding a non-targeting scramble 
sequence. Once stable clones were selected, cells were maintained in 
Puromycin-containing complete media. Successful knockdown of STMN1 
expression was assayed by qPCR and Western blot as described above.  
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Cell Proliferation Assay 
The Vybrant MTT Cell Proliferation Assay Kit (Life Technologies, 
Carlsbad, CA) was used to assess cell proliferation. 30,000 viable cells were 
seeded per well in a 96-well plate in a final volume of 100uL of phenol free 
complete media and phenol-free serum-free media. Every 24 hours, media 
was replaced and a plate was subjected to the assay by adding 10uL of 12mM 
MTT stock solution, as per manufacturer’s instructions. In brief, the plate was 
incubated at 37°C for 4 hours, after which point all but 25uL was removed and 
50uL of dimethyl sulphoxide (DMSO) (Sigma Aldrich, St. Louis, MO) was 
added to each well. The plate was incubated at 37°C for an additional 10 
minutes and absorbance was read in a microplate reader (iMARK, BioRad, 
Hercules, CA) at 490nm. Experiments were performed twice in quintuplet.  
 
Cell Cycle and Apoptosis Analysis 
For cell cycle analysis, 5x105 cells were seeded in 6-well plates 
overnight. Media was replaced with serum-free media in a subset of wells the 
following morning and cells were harvested and fixed after 48 hours of serum 
starvation by utilizing cold PBS and 70% cold ethanol, respectively. After 
fixation at 4°C for 2 days, cells were washed twice with PBS, treated with 
100ug/mL RNaseA for 30 minutes at 4°C, washed once with PBS, and stained 
with 50ug/mL propidium iodide (PI). The cells were analyzed by flow cytometry 
(Gallios, Beckman Coulter, Brea, CA) and cell-cycle stages were determined 
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using the Kaluza software (Beckman Coulter, Brea, CA). 20,000 events per 
sample were analyzed. For apoptosis analyses, the PE Annexin V Apoptosis 
Detection Kit I was used (BD Biosciences, San Jose, CA) according to the 
manufacturer’s instructions. Similarly, a subset of cells were serum-starved for 
48 hours before the cells and supernatant was harvested, washed with PBS, 
resuspended in 1x Binding Buffer. The cells were then stained with AnnexinV 
and 7AAD, incubated at room temperature for 15 minutes in the dark and 
analyzed by flow cytometry as above. The experiments were performed twice 
in sextuplet. 
 
Cell Migration Assay 
A scratch assay was used to assess for cell migration in vitro. Cells 
were seeded in 6 well plates and grown to ~60-80% confluence. A 200uL 
pipette tip was used to create a horizontal scratch across the plate at three 
locations. Complete media was changed every 3 days. Cells were 
photographed daily and percent migration was measured in 6 fields using 
ImageJ software. The experiment was performed twice. 
 
Cell Invasion Assay 
The extent of cell invasion was assessed with the Cytoselect 24-well 
Cell Invasion Assay (Cell Biolabs Inc, San Diego, CA) according to the 
manufacturer’s instructions. A total of 2x105 cells in serum free media were 
seeded onto inserts (8uM pore-sized pre-coated extracellular basement 
12	  
membrane). The inserts were placed in a 24-well plate containing complete 
media. The plates were incubated for 48h at 37°C. Cells that invaded the 
matrix to the lower surface of the membrane were stained and counted under 
a light microscope. Four fields in 4 separate quadrants of each membrane 
were counted and averaged. The experiment was performed twice. 
 
Soft Agar Anchorage-Independent Growth Assay 
 Two-layered soft agar assays were performed in 6-well plates. The 
bottom layer of agar (1ml/well) contained 0.5% agar (Sigma Aldrich, St. Louis, 
MO) in maintenance medium. 50,000 cells in maintenance medium were 
mixed with agarose for a 0.35% solution and allowed to solidify atop the agar 
layer. This was then overlaid with 2mL complete media and allowed to grow at 
37°C in 5% CO2. Media was changed twice per week. After 3 weeks of culture, 
cell colonies were stained with 0.005% crystal violet solution and examined by 
microscopy. Colonies were counted in four separate fields per well and 
summed for each of 6 replicates. The experiment was performed twice. 
 
 
Statistical Analysis 
Calculations to determine significance in all experiments except RNA 
sequencing analyses (for which the methods are described above) were 
carried out using Pearson’s chi-squared test, student’s T-test, Mann-Whitney 
U-test, one-way Analysis of Variance, or Kruskal-Wallis test, as appropriate. 
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Continuous variables that followed a normal distribution are presented as 
mean ± standard deviation (SD), while those that were not normally distributed 
are presented as median (range).  A p-value of less than 0.05 was considered 
statistically significant.  All statistical analyses (except those performed for 
RNA sequencing analysis, as described above) were performed using STATA 
version 13.0 (College Station, TX).   
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RESULTS 
 
STMN1 expression is markedly increased in ACC compared to AA and NML 
RNA-sequencing analyses identified >300 genes that met our inclusion 
criteria for highly differentially expressed cytosolic proteins as described in the 
methods section. Figure 1A represents the top 20 most differentially 
expressed genes between benign (AA+NML) and malignant samples (ACC). 
STMN1 was among the top differentially expressed genes in ACC, with more 
than an 8-fold increase of STMN1 expression in malignant over benign 
adrenal tissue (p<2.4E-07) (Figure 1B). The expression of STMN1 was 
validated by qPCR and Western Blot (Figure 2A,B), which demonstrated 
distinctly higher expression of STMN1 in ACC samples and established ACC 
cell line, NCI-H295R, compared to normal adrenal cortex and adrenal 
adenoma samples. STMN1 Expression in ACC 
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We further investigated protein expression using IHC on a tissue 
microarray composed of 51 samples and found significantly higher STMN1 
expression compared to NML and AA (Figure 2C-F). Wide distribution of 
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STMN1 was detected in the majority of tumor cells in ACC. To confirm our 
findings, we compared IHC staining of STMN1 on an independent TMA (MDA 
TMA) and found a stronger staining pattern overall and a similarly high 
expression of STMN1 in ACC samples relative to both NML and AA (Figure 
2G).  Available clinical characteristics of patients represented by both TMAs, 
including age, sex, biochemical profile, presence of metastases, 
histopathologic features (e.g. Weiss score), and length of followup, were not 
significantly different (data not shown).   
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Effect of STMN1 knockdown on cellular proliferation, cell cycle and apoptosis 
in ACC cell line 
Given the high expression of STMN1 in ACC, we next investigated the 
phenotypic effects of STMN1 knockdown in adrenocortical carcinoma cells 
using the NCI-H295R cell line to investigate STMN1’s ACC oncogenic 
potential. Stable knockdown of STMN1 was achieved via lentiviral-assisted 
shRNA transfection using puromycin selection. We achieved a 70% 
knockdown of SMTN1 expression at the mRNA level and a 78% knockdown of 
protein expression compared to control cells transfected with a scrambled 
sequence (Figure 3A,B). 
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Figure 3. Lentiviral-assisted stable knockdown of STMN1 in NCI-H295R cells. (A) Expression of 
STMN1 mRNA without transfection (H295R) and after transfection with scramble shRNA (Control) 
and STMN1-shRNA (ΔStmn1) normalized to GAPDH using the (2-ΔΔCT) method. (B) 
Representative Western blot demonstrating decreased protein expression of knockdown cells 
(ΔStmn1) compared to untreated cells (H295R) and cells treated with scramble shRNA (Control). 
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 The effect of STMN1 knockdown on cell viability was investigated using 
the MTT assay. No significant difference was seen between control and 
STMN1 knockdown NCI-H295R cells (ΔSTMN1)(Figure 4A). Next, to simulate 
a tumor microenvironment, we cultured these cells in serum-free conditions. 
Cell viability was modestly reduced in knockdown cells compared to control 
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when serum was removed, p<0.01 (Figure 4B). This effect was seen starting 
at 24 hours. Cell cycle analysis (Figure 4C) demonstrated a greater proportion 
of cells remaining in G0/G1 under stressed conditions (76.9% vs. 73.5%, 
p<0.01 in ΔSTMN1 vs. control, respectively) compared to regular growth 
media (68.7% vs. 66.2%, p=0.09 in ΔSTMN1 vs. control, respectively). 
Assessing apoptotic processes, we found a significantly greater proportion of 
viable cells (41.5% vs. 13.4%, p<0.01) and fewer apoptotic cells (39.6% vs. 
73.3%, p<0.01) in the control group compared with the knockdown under 
serum-free conditions (Figure 4D). No significant difference was found in cell 
cycle or apoptosis between the STMN1-infected cells and control cells in 
regular serum-containing media. These results indicate that under stressed 
conditions, the loss of STMN1 induced apoptosis and cell-cycle arrest at 
G0/G1. 
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Figure 4. (A, B) Effect of STMN1 knockdown on cellular 
proliferation, representing mean data from two independent 
experiments performed in quintuplet. STMN1 knockdown 
and Control NIH-H295R cells were grown in normal media 
(A) and serum-free (SF) media (B). (C) Effect of STMN1 
knockdown on cell cycle. Cells were grown in regular 
media and SF media for 48 hours prior to analysis. Data 
represents two independent experiments.  (D) Effect of 
STMN1 knockdown on apoptosis. Cells were grown in 
regular media and SF media for 48 hours prior to analysis. 
Experiments were performed in duplicate. Student’s t-test 
was used for pairwise statistical comparisons. 
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Effect of STMN1 knockdown on cell migration and invasion 
 To investigate STMN1’s role in cellular motility and invasive potential, 
we subjected transfected cells to a scratch assay for 5 days. ΔSTMN1 cells 
were found to migrate 11% less than control cells transfected with scramble 
shRNA (p<0.05) as shown in Figure 5A, B. Cellular invasion was assessed 
using a Boyden Chamber assay after 48 hours of incubation. Cells transfected 
with STMN1-shRNA demonstrated less invasive ability than control cells 
transfected with scramble-shRNA (p<0.05), Figure 5C. 
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STMN1 knockdown decreases tumorogenicity in NCI-H295R 
 To further evaluate the phenotypic changes incurred by STMN1 
knockdown, we performed the soft-agar anchorage-independent growth assay. 
ΔSTMN1 cells formed significantly fewer colonies in soft agar after three 
weeks of incubation compared to control (Figure 5D,E; 837 vs. 637 colonies, 
p<0.01) suggesting STMN1 contributes to tumorigenesis.  
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Figure 5.  (A) 
Representative images of 
cell migration at Time=0 
and T=5 days in control 
and STMN1 knockdown 
cells. (B) Quantitative 
assessment of cell 
migration from two 
independent experiments. 
(C) Effect of STMN1 
knockdown on cell invasion 
showing significantly 
decreased invasion ability 
of STMN1 knockdown 
cells. Data representing 
two independent 
experiments. (D) 
Representative images of 
reduced anchorage-
dependent growth in soft 
agar with the loss of 
STMN1, showing colony 
formation after 3 weeks of 
incubation. (E) Quantitative 
assessment of colony 
formation. Data 
representing two 
independent experiments. 
Student’s t-test was used 
for pairwise statistical 
comparisons in B, C, and 
E. 
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DISCUSSION 
 
STMN1 is a cytosolic protein that plays an important regulatory role in 
microtubule dynamics. It was originally described as being overexpressed in 
leukemia and lymphoma [30], and has since been described in multiple solid 
organ human malignancies where it is correlated with aggressive cellular 
behavior as well as poor clinicopathologic and prognostic features 
[14,16,17,19,31]. Furthermore, investigations into inhibition of STMN1 with or 
without compounding strategies have shown promise for an anti-STMN1 
approach as a potential therapeutic target [21–23]. We sought to understand 
whether STMN1 contributes to the pathogenesis of adrenal cortical carcinoma 
as a gateway for further investigation into its therapeutic potential.  
 We submitted human adrenocortical carcinoma samples from a single 
institution for RNA sequencing and found STMN1 to be highly overexpressed 
in ACC compared to benign adrenal samples. To elucidate the functional 
consequences of STMN1 knockdown, we employed lentiviral-mediated 
STMN1 shRNA in the ACC cell line NCI-H295R and evaluated proliferation, 
invasion, migration and colony formation. Furthermore, in order to simulate a 
tumor microenvironment devoid of nutrients and growth factors, we stressed 
cells in our experiments by removing serum from cell culture media, as 
previously described [32–34]. In doing so, we found significant effects on 
cellular viability, cell-cycle progression, apoptosis, and invasion.  
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These results suggest that STMN1 overexpression confers a survival 
advantage or escape mechanism and silencing its expression may be a 
mechanism to curb aggressive proliferation.  While the mechanism behind this 
relationship is still elusive, insights into how STMN1 regulates microtubules 
and proliferation have been suggested by Rubin and Atweh [35]. They 
hypothesize that STMN1 plays a critical role in the formation of the normal 
mitotic spindle upon entry into mitosis but also in the regulation of function in 
later stages of mitosis and its timely exit from this cell-cycle process. 
Specifically, they report that expression of a constitutively active form of 
STMN1 arrests cells early in mitosis and prevents further progression through 
the cell cycle. Lu et al [36] suggest that the microtubule destabilizing activity of 
STMN1 plays a crucial role in initiating the epithelial-mesenchymal transition 
(EMT) by contributing to a ‘stathmin-microtubule-EMT’ axis during cancer 
development, resulting in features such as high invasiveness and drug 
resistance [36].   
 Furthermore, among other highly regulated processes essential to 
normal cellular function is apoptosis. Dysregulation of apoptosis has been 
widely implicated in the development of cancer, as malignant cells are often 
dependent on aberrant apoptosis to escape cell death. As such, the apoptotic 
pathway has been an attractive target for the development of therapeutics [37]. 
In this study, we found that silencing STMN1 significantly increased apoptosis 
in H295R cells, suggesting the potential therapeutic utility of this approach. 
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 The role of STMN1 in the tumorigenesis of ACC is further suggested by 
our findings that silencing STMN1 decreased migration, invasion, and 
anchorage-independent growth of ACC tumor cells. Similar findings have been 
reported in esophageal adenocarcinoma, endometrial adenocarcinoma and 
oral squamous cell carcinoma, among others [15,18,19].  
 Finally, STMN1 overexpression has been linked to chemoresistance to 
taxanes and vinblastine (chemotherapeutic drugs that target microtubules) in 
some tumor types. In breast cancer, Alli et al. showed that overexpression of 
STMN1 decreased sensitivity of paclitaxel and vinblastine and suggested it did 
so by altering drug binding and inducing arrest of the cell cycle [38]. In 
esophageal cancer, Wan et al. showed that silencing STMN1 increased 
sensitivity to the same drugs [23]. Further, in NCI-H295R cells, Fallo et al. 
reported an antiproliferative effect from paclitaxel by inducing apoptosis [39]. 
Future studies combining STMN1 silencing with microtubule-targeting drugs 
are warranted. 
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CONCLUSION 
 
 In adrenocortical carcinoma, therapeutic options for advanced disease 
are lacking. With the advent of novel technologies such as genetic profiling, 
small molecule inhibitors and precision medicine, we are offered novel and 
potentially more viable options for the treatment of these rare and lethal 
cancers. Although further studies are needed to determine the viability of 
STMN1 as a therapeutic target in ACC, our study provides evidence 
supporting its relevance to the tumorigenesis of ACCs.   
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